CompletedNCT07611812Updated May 28, 2026

Real-World Patterns of Utilization of Lenalidomide-based Triplet Regimens in FIrst RElapsed Multiple Myeloma Patients: Evidence From Medical Record Review

An observational study in Multiple Mieloma, First Relpase and Rd-base Triplet, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Observational

Study type: Observational
Model: Case-control
Time perspective: Retrospective
Enrollment: 100
Ages: 18 Years and older
Sex: All

Study summary

To compare progression-free survival (PFS) in patients with first-relapse multiple myeloma treated with Rd-based "triplets" (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs. Elotuzumab + Rd (EloRd) vs. Ixazomib + Rd (IxaRd))

Conditions studied

Multiple Mieloma
First Relpase
Rd-base Triplet

In context

Lead sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia is the lead sponsor of 255 studies on the registry; 113 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Sampling method: Non-probability sample

Study population

Patients referred to the hematology department of the coordinating center and the participating centers

Inclusion criteria

Patients with multiple myeloma (MM) at first relapse treated starting in January 2017 with RD-based triplets in accordance with current clinical practice
Age ≥18 years
Written informed consent signed by the patient

Exclusion criteria

Exclusion Criteria:

the patient's refusal to participate

Study design

Observational model: Case-control
Time perspective: Retrospective
Enrollment: 100 participants (actual)
Patient registry: No

What researchers measure

Primary outcomes

Comparison of progression-free survival (PFS) in patients with multiple myeloma at first relapse treated with Rd-based "triplet" regimens (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs Elotuzumab + Rd (EloRd) vs Ixazomib + Rd (IxaRd))
Time frame: The study is expected to run for 24 months starting with the enrollment of the first patient in November 2020

Study locations

1 site

Fondazione IRCCS Policlinico San Matteo
Pavia, 27100, Italy

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT07611812
Lead sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia
Responsible party: Silvia Mangiacavalli (MD, Fondazione IRCCS Policlinico San Matteo di Pavia) — Principal investigator
First posted: May 28, 2026
Start date: Feb 4, 2021
Primary completion: Dec 31, 2024
Completion: Dec 31, 2025
Last update: May 28, 2026

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Start the discussion